People In The News

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Illumina has appointed Elizabeth Brady to be VP of global supply chain and Emily Winn-Deen to be VP of diagnostics development.

Brady, who formerly was a VP at Boston Scientific, will run global sourcing, planning, logistics, and distribution operations. Winn-Deen previously was VP of Genetics and Oncology R&D at Cepheid, and she was involved in diagnostics at Roche Molecular Systems, Applera, Oncor, and Bayer Diagnostics.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.